Vernalis up as Parkinson's drug passes safety trial
The drug development firm Vernalis has reported a successful outcome in Phase I trials of its V81444 treatment that may be useful in the fight against Parkinson's disease.
The drug development firm Vernalis has reported a successful outcome in Phase I trials of its V81444 treatment that may be useful in the fight against Parkinson's disease.
The double-blind, placebo-controlled study showed "a wide range of doses were found to be well tolerated with no unexpected safety findings."
The focus now shifts to a "receptor occupancy" study, scheduled to start in the second half of 2012.
Subscribe to MoneyWeek
Subscribe to MoneyWeek today and get your first six magazine issues absolutely FREE

Sign up to Money Morning
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
By 11:19 Vernalis shares had risen 1.4%.
BS
Sign up for MoneyWeek's newsletters
Get the latest financial news, insights and expert analysis from our award-winning MoneyWeek team, to help you understand what really matters when it comes to your finances.
MoneyWeek is written by a team of experienced and award-winning journalists, plus expert columnists. As well as daily digital news and features, MoneyWeek also publishes a weekly magazine, covering investing and personal finance. From share tips, pensions, gold to practical investment tips - we provide a round-up to help you make money and keep it.
-
Trouble brews in B&M as bargain shops take a hit
Opinion Once a stock market darling, B&M's share price has slumped. What has gone wrong for bargain shops?
-
US and China reach a ceasefire in their trade war after talks in London
The US and China's trading relationship – the most important one in the global economy – is back on track. Will the truce last?